The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration

Small cell lung cancer (SCLC) is an aggressive malignancy representing 15% of lung cancers. Good evidence exists to guide upfront treatment, however upon relapse there is only modest prospective evidence available to guide management. Clinical trials are challenging due to the aggressive natural history, urgency to begin therapy, high incidence of brain metastases, and frequent comorbidities in the affected patient population. Therefore, extrapolation of clinical trial results to the general population is troublesome.